Original Query: ALL
Previous Study | Return to List | Next Study

Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency (KAMPER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01016392
Recruitment Status : Active, not recruiting
First Posted : November 19, 2009
Last Update Posted : January 24, 2018
Information provided by (Responsible Party):
BioMarin Pharmaceutical

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2024
  Estimated Study Completion Date : December 2024